RESEARCH ARTICLE
MicroRNA155 Expression in Relation to BDCAF Scored Behçet's Disease in an Egyptian Patients' Sample
Sally S. Hassouna1, *, Manal Y. Tayel1, Dalal M. ElKaffash2, Ahmed M. Abdelhady3, Eman H. Elsayed1
Article Information
Identifiers and Pagination:
Year: 2018Volume: 12
First Page: 115
Last Page: 122
Publisher ID: TORJ-12-115
DOI: 10.2174/1874312901812010115
Article History:
Received Date: 14/4/2018Revision Received Date: 19/5/2018
Acceptance Date: 22/6/2018
Electronic publication date: 31/7/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Objective:
To discover the possibility of using microRNA155 (miRNA155) expression level as a biomarker of Behçet's Disease (BD) activity or remission.
Methods:
Thirty BD patients’ white blood cells (WBCs) miRNA155 expression was measured and compared to WBCs miRNA155 expression in 15 healthy subjects. Assessment of disease activity was done using Behçet's Disease Current Activity Form (BDCAF).
Results:
miRNA155 expression significantly decreases with the increase of BD activity scored by BDCAF.
Conclusion:
Increased miRNA155 may be used as a biomarker of BD remission and thus in the disease follow up. There could be a prospect of treating the disease via microRNA 155 effect enhancement.